Chemically Programmable Antibody-Drug Conjugates: Strategies from Targeting Programmability to Payload Activation
DOI:
https://doi.org/10.54097/k2468v26Keywords:
antibody-drug conjugates, chemical programmability, targeting programmability, click chemistry, bioorthogonal chemistry.Abstract
Antibody-drug conjugates (ADCs) are now highly effective anticancer drugs, but their molecular functions are relatively fixed at the time of production and cannot adapt to changes in the tumor microenvironment. Chemical programmability refers to the ability to modify a predefined antibody platform after scaffold construction by exchanging, activating, or reorganizing functional modules, providing modularity and control over various functional levels in ADC design through a versatile antibody platform that can be chemically altered in terms of targeting and effector functions. Hardware-level programmability refers to the engineering of universal antibody scaffolds and conjugation sites; software-level programmability refers to exchangeable targeting ligands, payloads and release mechanisms that define therapeutic functions. The five functional levels of chemically programmable strategies are: targeting programmability, assembly programmability, target-engagement programmability, conjugation programmability, and payload-activation programmability. We trace the conceptual origins to chemically programmed antibodies using catalytic antibody 38C2 and examine the core chemical toolbox, including inverse electron-demand Diels-Alder click chemistry, click-to-release technology, sulfur (VI) fluoride exchange chemistry, and non-canonical amino acid-based conjugation. These tools have been applied in four ways: in vivo click-driven assembly, small-molecule reprogramming, antibody fragment platforms and bispecific ADCs. Key challenges are discussed alongside future directions such as integrated multi-level programmable design.
Downloads
References
[1] Narayan, P., Osgood, C. L., Singh, H., Chiu, H.-J., Ricks, T. K., Chiu Yuen Chow, E., Qiu, J., Song, P., Yu, J., Namuswe, F., Guiterrez-Lugo, M., Hou, S., Pierce, W. F., Goldberg, K. B., Tang, S., Amiri-Kordestani, L., Theoret, M. R., Pazdur, R., & Beaver, J. A. (2021). FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer. Clinical Cancer Research, 27(16), 4478–4485. https://doi.org/10.1158/1078-0432.CCR-20-4557 DOI: https://doi.org/10.1158/1078-0432.CCR-20-4557
[2] Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., Yu, Z., Zhao, L., He, M., Wang, Y., Fu, C., Wei, M., & Yu, L. (2025). Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals. Journal of Hematology and Oncology, 18(1), Article 51. https://doi.org/10.1186/s13045-025-01704-3 DOI: https://doi.org/10.1186/s13045-025-01704-3
[3] Wang, X., Hou, X., Tan, L., Chen, C., Chang, L., Han, B., Xing, Y., Zeng, Z., Zhou, Z., Lu, Q., Xie, L., Lu, Z., Zhao, K., Cao, B., Liu, T., & Wang, Y. (2026). Tumor Microenvironment-Responsive Antibody Fragment-Cleavable PEGylated Drug Conjugates (AFCDC) for Improved Tumor Penetration and Antitumor Efficacy. Journal of Medicinal Chemistry, 69(9), 10169–10182. https://doi.org/10.1021/acs.jmedchem.5c03215 DOI: https://doi.org/10.1021/acs.jmedchem.5c03215
[4] Hao, Y., & Song, Z. (2025). Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies. Cancer Drug Resistance, 8, Article 59. https://doi.org/10.20517/cdr.2025.148 DOI: https://doi.org/10.20517/cdr.2025.148
[5] Simó, C., Vanover, A. C., D’Oliveira Albanus, R., Panikar, S. S., Shmuel, S., Benton, A., Giraldo-Guzman, J., Luna, J. M., Xu, Y., Berry, N. K., Keltee, N., Liu, J., Dehdashti, F., & Pereira, P. M. R. (2026). Modular in vivo antibody–ADC click to reverse drug resistance in tumours. Nature (London). https://doi.org/10.1038/s41586-026-10789-w DOI: https://doi.org/10.1038/s41586-026-10789-w
[6] Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024). Exploring the next generation of antibody–drug conjugates. Nature Reviews. Clinical Oncology, 21(3), 203–223. https://doi.org/10.1038/s41571-023-00850-2 DOI: https://doi.org/10.1038/s41571-023-00850-2
[7] Gu, Y., Wang, Z., & Wang, Y. (2024). Bispecific antibody drug conjugates: Making 1+1>2. Acta Pharmaceutica Sinica. B, 14(5), 1965–1986. https://doi.org/10.1016/j.apsb.2024.01.009 DOI: https://doi.org/10.1016/j.apsb.2024.01.009
[8] Yang, Y., Zhou, H., Tang, L., Qiu, S., Han, Y., Ji, D., Chen, X., Lei, F., Qu, S., Deng, B., Chen, L., Huang, J., Guo, Y., Liu, Z., Chen, D., Li, J., Shu, X., Qin, Y., Fu, Z., … Zhang, L. (2025). Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China. The Lancet (British Edition), 406(10516), 2235–2243. https://doi.org/10.1016/S0140-6736(25)01954-3 DOI: https://doi.org/10.1016/S0140-6736(25)01954-3
[9] Guo, F., Das, S., Mueller, B. M., Barbas, C. F., Lerner, R. A., & Sinha, S. C. (2006). Breaking the One Antibody-One Target Axiom. Proceedings of the National Academy of Sciences - PNAS, 103(29), 11009–11014. https://doi.org/10.1073/pnas.0603822103 DOI: https://doi.org/10.1073/pnas.0603822103
[10] Wagner, J., Lerner, R. A., & Barbas, C. F. (1995). Efficient Aldolase Catalytic Antibodies That Use the Enamine Mechanism of Natural Enzymes. Science (American Association for the Advancement of Science), 270(5243), 1797–1800. https://doi.org/10.1126/science.270.5243.1797 DOI: https://doi.org/10.1126/science.270.5243.1797
[11] Rader, C., Sinha, S. C., Popkov, M., Lerner, R. A., & Barbas, C. F. (2003). Chemically Programmed Monoclonal Antibodies for Cancer Therapy: Adaptor Immunotherapy Based on a Covalent Antibody Catalyst. Proceedings of the National Academy of Sciences - PNAS, 100(9), 5396–5400. https://doi.org/10.1073/pnas.0931308100 DOI: https://doi.org/10.1073/pnas.0931308100
[12] Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017). Strategies and challenges for the next generation of antibody–drug conjugates. Nature Reviews. Drug Discovery, 16(5), 315–337. https://doi.org/10.1038/nrd.2016.268 DOI: https://doi.org/10.1038/nrd.2016.268
[13] Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020). Antibody–Drug Conjugates: A Comprehensive Review. Molecular Cancer Research, 18(1), 3–19. https://doi.org/10.1158/1541-7786.MCR-19-0582 DOI: https://doi.org/10.1158/1541-7786.MCR-19-0582
[14] Joubert, N., Beck, A., Dumontet, C., & Denevault-Sabourin, C. (2020). Antibody–Drug Conjugates: The Last Decade. Pharmaceuticals (Basel, Switzerland), 13(9), Article 245. https://doi.org/10.3390/ph13090245 DOI: https://doi.org/10.3390/ph13090245
[15] Rader, C. (2014). Chemically programmed antibodies. Trends in Biotechnology (Regular Ed.), 32(4), 186–197. https://doi.org/10.1016/j.tibtech.2014.02.003 DOI: https://doi.org/10.1016/j.tibtech.2014.02.003
[16] Popkov, M., Rader, C., Gonzalez, B., Sinha, S. C., & Barbas, C. F. (2006). Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector. International Journal of Cancer, 119(5), 1194–1207. https://doi.org/10.1002/ijc.21924 DOI: https://doi.org/10.1002/ijc.21924
[17] Cilliers, C., Menezes, B., Nessler, I., Linderman, J., & Thurber, G. M. (2018). Improved Tumor Penetration and Single-Cell Targeting of Antibody–Drug Conjugates Increases Anticancer Efficacy and Host Survival. Cancer Research (Chicago, Ill.), 78(3), 758–768. https://doi.org/10.1158/0008-5472.CAN-17-1638 DOI: https://doi.org/10.1158/0008-5472.CAN-17-1638
[18] Tsumura, R., Manabe, S., Takashima, H., Koga, Y., Yasunaga, M., & Matsumura, Y. (2018). Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor. Journal of Controlled Release, 284, 49–56. https://doi.org/10.1016/j.jconrel.2018.06.016 DOI: https://doi.org/10.1016/j.jconrel.2018.06.016
[19] Rudnick, S. I., Lou, J., Shaller, C. C., Tang, Y., Klein-Szanto, A. J. P., Weiner, L. M., Marks, J. D., & Adams, G. P. (2011). Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors. Cancer Research (Chicago, Ill.), 71(6), 2250–2259. https://doi.org/10.1158/0008-5472.CAN-10-2277 DOI: https://doi.org/10.1158/0008-5472.CAN-10-2277
[20] Walsh, S. J., Bargh, J. D., Dannheim, F. M., Hanby, A. R., Seki, H., Counsell, A. J., Ou, X., Fowler, E., Ashman, N., Takada, Y., Isidro-Llobet, A., Parker, J. S., Carroll, J. S., & Spring, D. R. (2021). Site-selective modification strategies in antibody-drug conjugates. Chemical Society Reviews, 50(2), 1305–1353. https://doi.org/10.1039/d0cs00310g DOI: https://doi.org/10.1039/D0CS00310G
[21] Aigbogun, O. P., Phenix, C. P., Krol, E. S., & Price, E. W. (2023). The Chemistry of Creating Chemically Programmed Antibodies (cPAbs): Site-Specific Bioconjugation of Small Molecules. Molecular Pharmaceutics, 20(2), 853–874. https://doi.org/10.1021/acs.molpharmaceut.2c00821 DOI: https://doi.org/10.1021/acs.molpharmaceut.2c00821
[22] Li, F., Emmerton, K. K., Jonas, M., Zhang, X., Miyamoto, J. B., Setter, J. R., Nicholas, N. D., Okeley, N. M., Lyon, R. P., Benjamin, D. R., & Law, C.-L. (2016). Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. Cancer Research (Chicago, Ill.), 76(9), 2710–2719. https://doi.org/10.1158/0008-5472.CAN-15-1795 DOI: https://doi.org/10.1158/0008-5472.CAN-15-1795
[23] Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., Hirai, T., Atsumi, R., Nakada, T., Hayakawa, I., Abe, Y., & Agatsuma, T. (2016). DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clinical Cancer Research, 22(20), 5097–5108. https://doi.org/10.1158/1078-0432.CCR-15-2822 DOI: https://doi.org/10.1158/1078-0432.CCR-15-2822
[24] Desnoyers, L. R., Vasiljeva, O., Richardson, J. H., Yang, A., Menendez, E. E. M., Liang, T. W., Wong, C., Bessette, P. H., Kamath, K., Moore, S. J., Sagert, J. G., Hostetter, D. R., Han, F., Gee, J., Flandez, J., Markham, K., Nguyen, M., Krimm, M., Wong, K. R., … Lowman, H. B. (2013). Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index. Science Translational Medicine, 5(207), Article 207ra144. https://doi.org/10.1126/scitranslmed.3006682 DOI: https://doi.org/10.1126/scitranslmed.3006682
[25] Tomarchio, E. G., Turnaturi, R., Saccullo, E., Patamia, V., Floresta, G., Zagni, C., & Rescifina, A. (2024). Tetrazine–trans-cyclooctene ligation: Unveiling the chemistry and applications within the human body. Bioorganic Chemistry, 150, Article 107573. https://doi.org/10.1016/j.bioorg.2024.107573 DOI: https://doi.org/10.1016/j.bioorg.2024.107573
[26] Arun, V., Lee, M., Choi, H., Lee, S., Choi, J., Yoo, T. H., Kim, W., & Kim, E. (2025). Easy Access to Bioorthogonal Click-to-Release Reagent Bishydroxy-trans-cyclooctene (C2TCO) and Harnessing of Its Rapid Labeling and Dissecting Feature in Multicycle Imaging. Bioconjugate Chemistry, 36(5), 930–935. https://doi.org/10.1021/acs.bioconjchem.4c00495 DOI: https://doi.org/10.1021/acs.bioconjchem.4c00495
[27] Gao, W., Yang, X., Li, Q., Liu, Y., Huang, W., Xia, X., & Yan, D. (2025). Covalent Affibody‐Molecular Glue Drug Conjugate Nanoagent for Proximity‐Enabled Reactive Therapeutics. Advanced Science, 12(10), Article 2412273. https://doi.org/10.1002/advs.202412273 DOI: https://doi.org/10.1002/advs.202412273
[28] Kwon, N. H., Lee, J. H., Kim, Y., Hahn, Y. S., & Kwon, I. (2025). Albubody: an engineered scFv variant platform for site-specific drug conjugation and enhanced tumor efficacy. Journal of Controlled Release, 386, Article 114165. https://doi.org/10.1016/j.jconrel.2025.114165 DOI: https://doi.org/10.1016/j.jconrel.2025.114165
[29] Sinha, S., Huang, Z., & Felding-Habermann, B. (2008). Chemically programmed antibody-drug conjugates. Cancer Research, 68(9_Supplement), 4060. https://aacrjournals.org/cancerres/article/68/ 9_Supplement/4060/548901
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

